<DOC>
	<DOCNO>NCT02138799</DOCNO>
	<brief_summary>This study evaluate drug alters liver enzyme ( rifampin ) affect metabolism enzalutamide men measure concentration enzalutamide metabolites plasma .</brief_summary>
	<brief_title>A Study Evaluate How Drug That Alters Liver Enzymes ( Rifampin ) Affects Metabolism Enzalutamide Men</brief_title>
	<detailed_description>The study consist 2 randomized treatment arm . In arm subject receive single oral dose enzalutamide . In Arm 1 subject admit clinic Day -1 remain Day 3 . Each subject receive single oral dose enzalutamide , administer fasted condition Day 1 . Ambulant visit take place Day 4 Day 50 . Full PK profile obtain enzalutamide , Major Inactive Carboxylic Acid Metabolite ( M1 ) Active Metabolite N-desmethyl Enzalutamide ( M2 ) Day 1 Day 50 intake enzalutamide . In Arm 2 subject receives once-daily dose rifampin Days 1 21 . On Day 8 , single oral dose enzalutamide administer fasted condition concomitantly rifampin . Full PK profile obtain enzalutamide , M1 M2 Day 8 Day 57 intake enzalutamide . An End Study Visit ( ESV ) take place 7 10 day last PK sample early withdrawal . Safety assessment perform throughout study .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Subject Body Mass Index ( BMI ) least 18.5 great 29.9 kg/m2 screening . Subject must use condom sex pregnant woman . Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control . Male subject must donate sperm start screen throughout study period 90 day final study drug administration . Subject confirm CYP2C8 poor metabolizer status base genotyping analysis . Subject history seizure condition may predispose seizure . Historically currently convulsive medication drug may lower seizure threshold . History central nervous system ( CNS ) infection . Also history transient ischemic attack cerebrovascular accident without head trauma within 12 month enrollment ( Day 1 visit ) . Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Rifampin</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>CYP2D8</keyword>
	<keyword>Enzyme induction</keyword>
</DOC>